Novel delivery systems of atorvastatin should be evaluated for pharmacodynamics instead of pharmacokinetics.
Date
Abhijit A
AA
Nagarsenker
Mangal S
MS
D000284:Administration, Oral; D000818:Animals; D000069059:Atorvastatin; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D004655:Emulsions; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D008099:Liver / Q000378:metabolism; D011758:Pyrroles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D014018:Tissue Distribution
D004655:Emulsions; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin